GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (FRA:07X) » Definitions » Net Income From Continuing Operations

Annovis Bio (FRA:07X) Net Income From Continuing Operations : €-26.77 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Annovis Bio's net income from continuing operations for the three months ended in Mar. 2025 was €-5.12 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was €-26.77 Mil.

Annovis Bio Net Income From Continuing Operations Historical Data

The historical data trend for Annovis Bio's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Net Income From Continuing Operations Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial -4.49 -12.82 -23.91 -51.54 -23.48

Annovis Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -4.66 -11.39 -5.60 -5.12

Annovis Bio Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (FRA:07X) » Definitions » Net Income From Continuing Operations
Comparable Companies
SPRO ESLA HSTC KPTI ITRM CAMP ACRV PVCT COEP AVTX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ANVS:USA
Address
101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Website
https://www.annovisbio.com
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Annovis Bio Headlines

No Headlines